|
|
|
|
CME-Accredited Webcasts, Presentation and Audio Downloads
Personalized Therapies and Best Clinical Practices for Hematologic Malignancies
|
You may participate in any or all of the sessions for CME credit or a Certificate of Attendance after you review the required ACCME (Accreditation Council on Continuing Medical Education) information on this page.
|
|
Menu
|
|
Please read the Overview, Learning Objectives, and Faculty Disclosures before you continue to the CME-Accredited Activity. This is an Accreditation Council for Continuing Medical Education (ACCME®) requirement. When you are finished please scroll to the bottom of this page and click the link stating that you have read and understood the faculty disclosures.
Overview of This CME-Accredited Educational Activity
Your Options for Methods of Participation are:
- View and/or listen to any of the sessions (listed below) via an Adobe Flash Webcast
- Download any slides as Adobe Acrobat files
- Download any audio only as MP3s or Podcasts
- Request a DVD-ROM of all sessions
|
Sessions can be individually reviewed for credit. You can participate in as few or as many as you desire.
CME-Accredited Educational Activity Dates and Time to Complete
Date of release: May 10, 2011
Date expires (CME credit will not be avaliable): May 10, 2012
Average time to complete each individual session: 20 minutes
Time to complete entire activity: 8 hours
Overview
The primary objective is to help you treat your hematology patients with the optimal personalized approaches in order to improve patient outcomes and minimize drug-induced toxicities. This CME activity is especially designed to review practice-changing or "game-changing" clinical and scientific data on hematologic malignancies presented at the 2010 annual ASCO meeting, and at other important hematology meetings in 2010, including the June 2010 annual EHA meeting in Barcelona, the October 2010 ESMO meeting in Milan, and most recently at the December 2010 ASH Symposium on Orlando.
Educational Needs Summary
The following major educational needs for your practices have been identified for review in this activity:
- New data on the combination of rituximab plus bendamustine, or rituximab plus lenalidomide for Non-Hodgkin's Lymphoma needs to be reviewed.
- The new standard of care for follicular lymphoma is to use a maintenance therapy strategy based upon the PRIMA clinical study results and not to use observation for managing these patients.
- For patients with aggressive, relapsed, B-cell lymphoma the data from the VERTICAL and other published trials showing how to achieve better outcomes needs to be reviewed.
- For Hodgkin's Disease patients data regarding therapy with brentuximab has recently published clinical data showing that this strategy improves patient outcomes. This needs to be addressed.
- Data needs to be reviewed regarding adding a rituximab-targeted strategy to traditional chemotherapy for newly diagnosed patients with CLL that has demonstrated improved outcomes through both an overall survival and a progression-free survival advantage.
- For refractory CLL patients data needs to be reviewed to help improve outcomes when using either single-agent alemtuzumab or bendamustine, or other combinations the combinations of rituximab plus lenalidomide, or alemtuzumab plus fludarabine, and the use of single-agent lenalidomide or single-agent ofatumumab as additional options for CLL in the second-line or refractory setting.
- Cutaneous T-cell Lymphoma data to improve patient outcomes needs to be reviewed from the 2010 ASH and ASCO meetings.
- Peripheral T-cell Lymphoma data using pralatrexate, or bortezomib or forodesine to improve patient outcomes needs to be reviewed from the 2010 ASH and ASCO meetings needs to be reviewed.
- A new CML patient-management algorithm is evolving and is needed for both initial and refractory CML because there are now three drugs that are FDA-approved for CML, imatinib, nilotinib and dasatinib.
- How and when to perform mutation testing and/or using this information optimally in treatment planning and decision-making of CML patients needs to be reviewed.
- Data affecting outcomes with Acute Myelogenous Leukemia needs to be reviewed using the following drugs: lenalidomide, decitabine, azacitadine, vorinostat and midostaurin.
- For patients with Myelodysplastic Syndromes the newest efficacy data with lenalidomide plus HDAC inhibition, and with other strategies for this malignancy also needs to be reviewed.
- For patients with acute promyelocytic leukemia the phase II efficacy data with blinatumomab and the new data with arsenic trioxide as consolidation therapy may become a new standard for improving outcomes in APL. This needs to be reviewed.
- The significant efficacy data with the use of lenalidomide maintenance therapy for multiple myeloma patients needs a thorough review and update.
- The efficacy data with proteasome inhibition combined with either bortezomib or carfilzomib, and, lowered neuropathy with carfilzomib needs to be reviewed for multiple myeloma patients.
- The benefits of using panobinostat, lenalidomide or vorinostat along with bortezomib, and also perifosine experimentally, can improve MM patient outcomes. This needs a review.
- A review and update on the efficacy data is needed regarding zolendronic acid as an agent with a direct anti-tumor effect on multiple myeloma patient.
The following is list of all sessions
Session 1: CRITICAL QUESTIONS IN THE TREATMENT OF LYM PHOMAS AND HODGKIN'S DISEASE
Chair: Thomas Witzig |
| 1a. |
Case Study: Progress in the treatment of mantle cell lymphoma: applying the results of the most current clinical trials for both newly diagnosed patients and relapsed patients, a longitudinal review
André Goy
|
| 1b. |
Case Study: Devising the optimal treatment strategies for newly diagnosed and relapsed/refractory diffuse large B-Cell lymphoma (DLBCL)
Leo Gordon
|
| 1c. |
Case Study: Additional therapies for follicular lymphoma: managing the challenge of multiple first-line treatment options
Thomas Witzig
|
| 1d. |
Point-CounterPoint Debate: Follicular lymphoma patients who relapse following initial therapy should receive traditional alternative systemic treatment options rather than a stem cell transplant.
Pro: John Leonard
Con: Sonali Smith
|
| 1e. |
Roundtable Panel Discussion
Session #1 Faculty
|
|
1f. |
Case Study: New systemic options for the management of Hodgkin's Disease
Anas Younes |
| 1g. |
Case Study: Peripheral T-Cell Lymphoma: Therapeutic Advances and toxicity issues in optimal therapy selection across all lines of therapy
Owen O'Connor |
| 1h. |
Case Study: State-of-the Art Therapies for Primary Cutaneous T-Cell Lymphoma: Building the new treatment algorithm?
Steven Rosen |
| 1i. |
Case Study: Personalizing therapies for patients with chronic lymphocytic leukemia (CLL): What are the optimal clinical applications of chemotherapies and targeted therapies in the first-line setting?
Shuo Ma |
| 1j. |
Case Study: Relapsed or refractory CLL: what are the optimal systemic therapies for these patients?
Tate Shanafelt |
Session 2: CRITICAL QUESTIONS IN THE TREATMENT OF MULTIPLE MYELOMA
Chair: Vincent Rajkumar |
|
2a. |
Case Study: The optimal treatment of the non-transplant candidates with multiple myeloma: what are the emerging options and optimal strategies?
Vincent Rajkumar
|
|
2b. |
Case Study: What are the optimal treatment strategies for transplant-eligible candidates with multiple myeloma?
Nikhil Munshi |
|
2c. |
Q & A
Learners and Faculty |
Session 3: CRITICAL QUESTIONS IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA AND MYELODYSLASTIC SYNDROMES
Chair: Michael Deininger |
|
3a. |
Case Study: New treatment algorithms for initial and relapse therapies of chronic myelogenous leukemia (CML). What are the optimal therapeutic options?
Moshe Talpaz |
|
3b. |
Case Study: Best clinical practices for treating acute myeloid leukemia (AML): How do we integrate prognostic factors into optimal treatment decision-making?
Michael Deininger |
|
3c. |
Case Study: Management of a newly diagnosed patient with Acute Promyelocytic Leukemia (APL)
Martin Tallman |
|
3d. |
Case Study: Myelodysplastic Syndromes - Update 2011
Virginia Klimek |
|
3e. |
Case Study: Treatment of Acute Lymphoblastic Leukemia (ALL)
Tibor Kovacsovics |
|
3f. |
Roundtable Panel Discussion
Learners and Faculty |
|
|
|
Educational Objectives
At the conclusion of all of these enduring materials, you should be able to:
- Apply the clinical data regarding combination and single-agent therapy used in the first-line settings for B-cell and T-cell malignancies.
- Utilize the most current clinical data with anti-CD20-based maintenance therapy following induction therapy for follicular lymphoma.
- Explain the current treatment options for refractory or relapsed patients with B-cell lymphoma.
- Evaluate current and emerging strategies for treating Hodgkin's lymphoma.
- Apply the current clinical data with anti-CD20-based therapy for the first-line treatment of chronic lymphocytic leukemia.
- Explain the options for treating chronic lymphocytic leukemia in the refractory or relapsed settings.
- Review the clinical evidence for therapy selection for cutaneous T-cell lymphoma.
- Discuss the various treatment options for therapy of peripheral T-cell lymphoma.
- Apply the new treatment paradigm for initial therapy of chronic myelogenous leukemia for patients in the chronic phase of this malignancy.
- Apply the scientific and clinical data regarding patients with chronic myelogenous leukemia who are refractory or who relapse on initial therapy.
- Evaluate the evidence-based treatment options for acute myeloid leukemia.
- Examine the therapeutic options for treating myelodysplastic syndromes.
- Discuss the agents used to treat acute lymphoblastic and acute promyelocytic leukemias.
- Review the clinical data for initial and maintenance therapy with immunomodulatory agents for multiple myeloma patients.
- Utilize the clinical evidence with proteasome inhibition as a single-agent and in combination therapy for initial and maintenance therapy of multiple myeloma.
- Evaluate the expanding clinical applications of bone-directed therapy for multiple myeloma.
Target Audience
This CME activity is designed to meet the educational needs of hematologists, hematologist/oncologists, oncologists, radiation oncologists, surgical oncologists, pathologists, and other allied health-care professionals involved in the treatment, care and management of patients with hematologic malignancies, including physician assistants, nurse practitioners/nurses, pharmacists, and fellows. Hematology is treated optimally by a multidisciplinary approach of clinicians and, thus, all of the aforementioned clinician specialties are targeted for invitation to the personalized therapies and best clinical practices symposium for hematologic malignancies.
CME Accreditation & Credit Designation
The Biomedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Biomedical Learning Institute designates this enduring material for a maximum of 8 AMA PRA Category 1
Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CME Certificate or Certificate of Participation
The relevant section(s) of the Evaluation Form pertaining to the session(s) of the enduring materials you have viewed or listened to, and the Request for Credit Form must be completed and submitted to the Biomedical Learning Institute following your participation in the enduring material educational activity to obtain CME credit. Physicians and other participants will be able to print their certificates after they complete these Forms.
Disclosure of Conflicts of Interest
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by the Biomedical Learning Institute must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an BMLI-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. |
|
Faculty Disclosures
It is the policy of the Biomedical Learning Institute (BMLI) to ensure that all of its educational activities and materials are of the highest quality, and are balanced, objective, independent, free of commercial bias, and planned and developed with scientific rigor with strict adherence to all Accreditation Council for Continuing Medical Education (ACCME) rules and policies. The BMLI evaluates all content, faculty and faculty disclosures for any potential conflicts of interest. Should any conflicts of interest be identified these conflicts are resolved in advance of the educational activity by independent peer reviewers who are experts in the subjects of the educational activity.
All faculty and BMLI staff participating in the content, planning or implementation of an educational CME activity are required to disclose to the audience of the educational activity any relevant financial relationships or interests and to assist in the resolution of any conflict of interest that may arise from the relationship(s) or interest(s). It is also the policy of the BMLI to require all faculty presenters to make a meaningful disclosure to the audience of their discussions of unlabeled or FDA unapproved drugs, products, tests or devices. This information will be available as part of the educational activity and related material.
The following faculty and BMLI staff have reported real or potential relevant conflicts of interest and these conflicts have been resolved, prior to this educational activity through a peer-review process by two medical oncologists who have had no affiliation with this educational activity other than the peer review process. This is documented on this page immediately following the financial disclosures below.
Faculty Affiliations and Disclosures
Michael Deininger, MD, PhD
Chief, Division of Hematology and Hematologic Malignancies
M.M. Wintrobe Professor of Medicine
University of Utah
Huntsman Cancer Institute
Salt Lake City, UT
Consulting Fees: BMS, Ariad, Novartis
Contracted Research: BMS, Celgene, Genzyme
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation
|
|
S. Vincent Rajkumar, MD
Professor of Medicine
Division of Hematology
Department of Medicine
Mayo Clinic
Rochester, MN
I have no real or apparent conflicts of interest to report.
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
|
Leo I. Gordon, MD
Professor, Division of Hematology / Oncology
Division of Hematology/Oncology
Northwestern University
Robert H. Lurie Comprehensive Cancer Center
Chicago, IL
I have no real or apparent conflicts of interest to report.
|
|
Steven R. Rosen, MD, FACP
Director, Robert H. Lurie Cancer Center
Northwestern University
Chicago, IL
Consulting Fees: Allos, Genentech, Celgene, Abbott Laboratories, Millennium
Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Therakos, Genentech, Genzyme
Contracted Research: Celgene
|
André Goy, MD, MS
Chief, Lymphoma Division
The Cancer Center
Hackensack University Medical Center
Hackensack, NJ
Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Genentech, Millennium
|
|
Tait D. Shanafelt, MD
Associate Professor of Medicine
Division of Hematology
Department of Medicine
Mayo Clinic
Rochester, MN
Contracted Research: Genentech, Celgene, Cephalon, GSK, Hospira, Polyphenon E International
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
|
Virginia M. Klimek, MD
Associate Professor of Medicine
Leukemia Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY
Consulting Fees: Celgene
|
|
Sonali Smith, MD
Associate Professor of Medicine
Division of Hematology
Department of Medicine
University of Chicago Medical Center
Chicago, IL
Consulting Fees: Genentech, Pfizer, Celgene
Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Genentech, Biogen IDEC, Celgene
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
|
Tibor Kovacsovics, MD
Associate Professor of Medicine
Director, Acute Leukemia Program
Center for Hematologic Malignancies
Oregon Health & Science University
Portland, OR
Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Sigma Tau Pharmaceuticals
Contracted Research: Sigma Tau Pharmaceuticals
|
|
Martin S. Tallman, MD
Chief of Leukemia Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY
Consulting Fees: Genzyme
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
|
John P. Leonard, MD
Professor of Medicine
Weill Cornell Medical College
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medical College
New York, NY
Consulting Fees: GSK, EMD Serono, Sanofi-Aventis, Pfizer, Biotest Pharmaceuticals, Immunomedics, Cell Therapeutics, Celgene, Johnson & Johnson, Calistoga Pharmaceuticals, Cephalon, Biogen IDEC, Hospira, Millennium, Novartis, Facet Biotech, Seattle Genetics
|
|
Moshe Talpaz, MD
Professor, Department of Internal Medicine
Alexander J. Trotman Professor of Leukemia Research
Associate Director of Translational Research
Associate Chief/Director of Hematologic Malignancies
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI
Contracted Research: Novartis, BMS, Sanofi-Aventis, Ariad, Incyte, Takeda
|
Shuo Ma, MD, PhD)
Assistant Professor of Medicine
Division of Hematology/Oncology
Northwestern University
Robert H. Lurie Comprehensive Cancer Center
Chicago, IL
Consulting Fees: Genzyme
Contracted Research: GSK
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
|
|
Thomas E. Witzig, MD
Professor of Medicine
Division of Hematology
Department of Internal Medicine
Mayo Clinic
College of Medicine
Rochester, MN
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
|
Nikhil C. Munshi, MD
Associate Professor of Medicine
Harvard Medical School
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, MA
Consulting Fees: Celgene, Millennium, Novartis, Onyx
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
|
|
Anas Younes, MD
Director, Clinical and Translational Research Program
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas M.D. Anderson Cancer Center
Houston, TX
Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Genentech, Novartis, Sanofi-Aventis, SBIO, Seattle Genetics, Syndax
|
Owen A. O'Connor, MD
Chief, Division of Hematology and Medical Oncology
Deputy Cancer Center Director
NYU Cancer Institute
NYU Langone Medical Center
New York, NY
Contracted Research: Millennium, Abbott, Allos, Cougar, Cytokinetics, Proledix
Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Millennium
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
|
|
|
|
Peer Review Process of Conflicts of Interest
This educational activity has been independently peer-reviewed.
Disclosure of Unlabeled Uses
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the Physicians' Desk Reference.
The Biomedical Learning Institute (BMLI) does not recommend the use of any agent outside of the FDA labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the BMLI. Please refer to the official FDA prescribing information for each product for discussion of approved indicated, contraindications, and warnings.
Acknowledgement of Supporters
|
